| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Modified Organism
ALVAC‐HIV Vaccine
Record information and status
Record ID
116157
Status
Published
Date of creation
2021-06-30 19:07 UTC (austein.mcloughlin@cbd.int)
Date of publication
2021-06-30 19:07 UTC (austein.mcloughlin@cbd.int)

Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.

LMO name
ALVAC‐HIV Vaccine
Transformation event
vCP1521
Developer(s)
D.L. Skea
Deputy director Regulatory Affair
Sanofi Pasteur
PA
United States of America
Phone:4166672701
Email:Danna.Skea@sanofipasteur.com
Description
ALVAC‐HIV (vCP1521) vaccine is a modified Canarypox virus carrying three Human immunodeficiency virus 1 genes (gag, pol and env). After inoculation and entry into the host cell, the viral vector contains the necessary sequences to direct the transient expression of the HIV-1 proteins, which will be presented to the host immune system. Since the viral particle (and viral genome) cannot enter the nucleus, transcription and translation are restricted to the cytoplasm. Further, DNA integration and recombination with the host genome cannot also not occur. The modified virus is replication deficient in human cells and thus not expected to cause disease. However, the modified virus is expected to replicate in avian species and passive cell lines.

In addition to using a modified virus, some experimental dosing regimes have also included the use of a secondary protein subunit vaccine, AIDSVAX B/E, which is composed of recombinant gp120, an envelope protein on the surface of HIV.
Recipient Organism or Parental Organisms
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
Canarypox virus - CNPV
Point of collection or acquisition of the recipient organism
The original strain of Canarypox virus (Rentschler strain) was attenuated by serial passages on chicken embryo fibroblasts. The attenuated virus was plaque isolated and designated as ALVAC.
Characteristics of the transformation process
Vector
ALVAC
Techniques used for the modification
  • Recombinant DNA
Introduced or modified genetic elements
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
Envelope glycoprotein gp160 - Human immunodeficiency virus 1 - HIV-1
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Gag polyprotein - Human immunodeficiency virus 1 - HIV-1
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Pol polyprotein - Human immunodeficiency virus 1 - HIV-1
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
H6 Gene Promoter - Vaccinia virus - Poxvirus, Smallpox vaccine, VACV, VV, Vaccinia
I3L promoter - Vaccinia virus - Poxvirus, Smallpox vaccine, VACV, VV, Vaccinia
Notes regarding the genetic elements introduced or modified in this LMO
The HIV-1 gene sequences, which were inserted in the ALVAC vector, are:
• Envelope protein, consisting of the extracellular gp120 moiety of the ZM96 strain of HIV-1 linked to the transmembrane anchor gp41 from LAI strain of HIV-1. The env sequence is under the control of the Vaccinia virus H6 promoter.
• Gag polyprotein and Pol polyprotein, consisting of the gag gene encoding the entire Gag protein and a portion of the pol sequence sufficient to encode the protease function. The sequences were sourced from the LAI strain of HIV-1. The gag-pol gene sequences are under the control of the same Vaccinia virus I3L promoter.
LMO characteristics
Modified traits
Common use(s)
  • Vaccine